Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a large growth in short interest in April. As of April 30th, there was short interest totaling 751,721 shares, a growth of 4,565.6% from the April 15th total of 16,112 shares. Based on an average daily volume of 627,214 shares, the days-to-cover ratio is currently 1.2 days. Approximately 44.5% of the shares of the company are sold short.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Down 3.3%

Shares of NASDAQ:SNOA traded down $0.04 during midday trading on Monday, hitting $1.16. The stock had a trading volume of 91,709 shares, compared to its average volume of 116,580. The company’s 50-day moving average price is $2.20 and its 200-day moving average price is $3.00. The company has a market capitalization of $2.01 million, a P/E ratio of -0.57 and a beta of 1.28. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Tuesday, February 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $5.47 million. Sonoma Pharmaceuticals had a negative net margin of 19.04% and a negative return on equity of 42.56%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.